Skip to Content Skip to Search

About GSK

We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer.

  • £34bn

    turnover in 2020

  • 3

    global businesses

  • 300

    years of innovation

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, preventing and treating disease and keeping people well with our scientific and technical know-how and talented people.

Pharmaceuticals

T-cells attacking a cancer cell
Immune system T-cells attacking a cancer cell

Vaccines

Herpes zoster virus of shingles
Herpes zoster virus of shingles

Consumer Healthcare

Novamin, a key technology in Sensodyne
Novamin, a key technology in Sensodyne Repair and Protect

How we do it

Everyone at GSK is focused on our three long-term priorities - Innovation, Performance, Trust - underpinned by our ambition to build a more purpose and performance driven culture, aligned to our values.

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £4.6bn

    adjusted R&D investment in 2020

  • 40

    new medicines in development at FY 2020

  • 17

    new vaccines in development at FY 2020

Performance

We deliver growth by investing effectively in our business, developing our people and executing competitively.

  • £34bn

    turnover in 2020

  • £9bn

    adjusted operating profit in 2020

  • £5.4bn

    free cash flow in 2020

  • £4bn

    dividends paid in 2020

Trust

We are a responsible company. We commit to use our science and technology to address health needs, make our products affordable and available and be a modern employer.

  • 84%

    employee engagement score on our latest employee survey

  • £250m

    donated in 2020 to community health programmes

  • 1st

    in Access to Medicines Index since the assessment began in 2008

Key figures

Please refer to our quarterly results materials for further information on GSK’s financial performance.

Our geographies

  • £14.6bn (43%)

    US (+6% CER) sales turnover 2020

  • £8.2bn (24%)

    Europe (+1% CER) sales turnover 2020

  • £11.4bn (33%)

    International (flat CER) sales turnover 2020